Results 81 to 90 of about 46,872 (214)

Diabetic ketoacidosis with mild hyperglycemia associated with the use of canagliflozin. Report of one case with type 1 diabetes [PDF]

, 2017
Indexación: Web of Science; Scopus; Scielo.Diabetic ketoacidosis with mild hyperglycemia is a major complication of sodium-glucose cotransporter 2 inhibitors.
Garcia B., C., Novik, V., Oliva I., D.
core   +1 more source

Sodium-glucose co-transporter 2 inhibitors use and the risks of genital and urinary tract infection: What should we know?

Tzu Chi Medical Journal
Sodium-glucose co-transporter 2 (SGLT2) inhibitors have convincingly demonstrated efficacy in reducing cardiovascular (CV) and renal complications in patients with diabetes mellitus, chronic kidney disease, and heart failure.
Du-An Wu, Bang-Gee Hsu, Yu-Li Lin
doaj   +1 more source

Effect of sodium-glucose Co-transporter 2 inhibitors on MCP-1 and uromodulin levels in patients with type 2 diabetes mellitus

Clinical Epidemiology and Global Health
Background and aim: A class of anti-diabetic medications, namely Sodium Glucose Co-Transporter-2 (SGLT2) inhibitors, has shown their potential effects beyond glucose tolerance in Type 2 Diabetes Mellitus (T2DM) patients.
Mani Pathak, Haya Majid, Parvej Khan, Md Masoom, Rizwana Parveen, Prem Kapur, Sunil Kohli, Nidhi   +7 more
doaj   +1 more source

SGLT2 inhibitors: Beyond glycemic control

Journal of Clinical & Translational Endocrinology
Multiple randomized controlled trials have extensively examined the therapeutic effectiveness of sodium-glucose cotransporter 2 (SGLT2) inhibitors, ushering in a transformative approach to treating individuals with type 2 diabetes mellitus (DM). Notably, emerging reports have drawn attention to the potential positive impacts of SGLT2 inhibitors in ...
Irtiza Hasan, Tasnuva Rashid, Vishal Jaikaransingh, Charles Heilig, Emaad M. Abdel-Rahman, Alaa S. Awad   +5 more
openaire   +3 more sources

The effect of sodium glucose Co-transport 2 inhibitors on cognitive impairment and depression in type 2 diabetes mellitus patients

Clinical Epidemiology and Global Health
Background and aim: Type 2 diabetes mellitus (T2DM) is a prevalent metabolic disorder often associated with thyroid dysfunction. Sodium-glucose co-transport 2 (SGLT2) inhibitors, a novel class of medications for T2DM, have shown potential effects on ...
Ashurova Nodirahon, Haya Majid, Swati Waghdhare, Divya Vohora, Nidhi   +4 more
doaj   +1 more source

Antidiabeetilise ravi valik ja ravikombinatsioonid. Kuidas on muutunud meie arusaamine diabeedi ravist? [PDF]

, 2016
Eesti Arst 2016; 95(10):673 ...
Pärt, Moonika
core   +2 more sources

Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis

Scientific Reports, 2017
Previous trial evidence suggested potential risk of serious urinary tract infections (UTIs) and genital infections in type 2 diabetes patients using sodium glucose co-transporter-2 inhibitors (SGLT2) inhibitors.
Jiali Liu, Ling Li, Sheyu Li, Pengli Jia, Ke Deng, Wenwen Chen, Xin Sun   +6 more
doaj   +1 more source

Pharmacogenomics in diabetes mellitus:insights into drug action and drug discovery [PDF]

, 2016
Genomic studies have greatly advanced our understanding of the multifactorial aetiology of type 2 diabetes mellitus (T2DM) as well as the multiple subtypes of monogenic diabetes mellitus.
A American Diabetes, A Bossi, A Dornhorst, A Mullard, AA Tahrani, Adem Y. Dawed, AJ Mulherin, AK Daly, AK Daly, AL Gloyn, AM Simonis-Bik, AP Gjesing, AP Morris, AR Harper, AV Segre, C Cao, C Global Lipids Genetics, C Mizzi, CE Elks, CF Deacon, CJ Bailey, CJ Bailey, CJ Bailey, CS Greene, DB Goldstein, DB Goldstein, DF Carr, E Pearson, EA Stein, EJ Verspohl, ER Pearson, ER Pearson, ES Kang, Ewan R. Pearson, FM Gribble, FS Collins, GG Graham, H Carter, H Schunkert, H Yki-Jarvinen, H Zhang, Helle Krogh Pedersen, I Watanabe, IM Stratton, J Flannick, J Taneera, J Yang, J Yang, J Yang, JC Cohen, JC Cohen, JN Todd, JT Erler, K Forslund, K Suzuki, K Zhou, K Zhou, K Zhou, K Zhou, K Zhou, K Zhou, KA Jablonski, Kaixin Zhou, KJ Gaulton, KL Mohlke, L Rossetti, L Tarasova, L Van Gaal, LJ McCreight, LM t Hart, M Abifadel, M Hay, M Javorsky, M Javorsky, M Stumvoll, M Tamaki, M Zhang, MC Hsieh, MK Hellerstein, ML Becker, ML Becker, ML Becker, MR Nelson, MR Nelson, N Siva, N van Leeuwen, NM De Silva, O Gokalp, O Magger, P Csermely, PJ Connelly, PM Visscher, PM Visscher, Q Pei, R Kumashiro, R Sabino-Silva, R Santer, RA Miller, RB Prasad, RL Chang, RM Plenge, RR Holman, RW Koivula, S Mallal, S Semiz, SD Bailey, T Dujic, T Dujic, T Ideker, TJ Nicolson, V Lyssenko, V Steinthorsdottir, Y Feng, Y Shu, Y Shu, Y Zhang, Y Zhou, Z Schroner   +117 more
core   +3 more sources

Effect of Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase 4 Inhibitors on Cardiovascular Function in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease

Journal of Obesity & Metabolic Syndrome, 2019
Background : Randomized controlled trials demonstrated lowering risks of cardiovascular events with sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with type 2 diabetes mellitus (T2DM) and high cardiovascular risk.
Sook Jung Lee, Kook Hyung Lee, Hyun Geong Oh, Hye Ji Seo, Soo Jin Jeong, Chong Hwa Kim   +5 more
doaj   +1 more source

Medical management of obesity in Scandinavia 2016 [PDF]

, 2016
Peer ...
Astrup, Arne, Rissanen, Aila, Rössner, Stephan, Tonstad, Serena   +3 more
core   +2 more sources